Kevin Maki, PhD

Professional Bio:

Kevin C Maki, PhD, CLS, FNLA, FTOS, FACN Kevin C Maki, PhD is the Founder and Chief Scientist for Midwest Biomedical Research (Chicago, Illinois). He specializes in the design and conduct of clinical studies in human nutrition, metabolism and chronic disease risk factor management. Dr Maki is also Adjunct Professor and Dean’s Eminent Scholar in the Department of Applied Health Science at the Indiana University School of Public Health, Bloomington, Indiana. He is a Fellow of the National Lipid Association, The Obesity Society, and the American College of Nutrition, as well as a certified Clinical Lipid Specialist. He currently serves as President of the National Lipid Association (2022-2023 term) and is the incoming Editor-in-Chief for the Journal of Clinical Lipidology (starting July 2023). Dr. Maki has participated in more than 300 clinical trials and observational studies as an investigator, consultant, or statistician, and published more than 250 scientific papers, books and book chapters. He earned a PhD in Epidemiology from the University of Illinois at Chicago’s School of Public Health, and an MS in Preventive and Rehabilitative Cardiovascular Health from Benedictine University.

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: National Dairy Council(MODEST), Matinas Biopharma(SIGNIFICANT), Pharmavite(SIGNIFICANT), Acasti Pharma(SIGNIFICANT), 89Bio(MODEST), Beren Therapeutics(SIGNIFICANT), Bragg Live Products(SIGNIFICANT), General Mills(SIGNIFICANT), New Amsterdam Pharma(SIGNIFICANT), Pepsico(SIGNIFICANT) OFFICER, DIRECTOR ETC: National Lipid Association(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: National Dairy Council(SIGNIFICANT), National Cattlemen's Beef Association(SIGNIFICANT), Pharmavite(SIGNIFICANT), Acasti Pharma(SIGNIFICANT), Matinas BioPharma(SIGNIFICANT), Cargill(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Greenyn Biotechnology(SIGNIFICANT), Hass Avocado Board(SIGNIFICANT), Indiana University Foundation(SIGNIFICANT), Naturmega(SIGNIFICANT)

View Full Disclosure